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Our understanding of infectious endocarditis (IE) has
grown in conjunction with some of the major advances in
the history of medicine (1). One of the earliest reports of the
disease comes from Lazere Riviere, who in 1646 reported on
a patient who suffered from progressive shortness of breath
and a palpable murmur over the heart. At autopsy, Riviere
found “small round outgrowths, the largest of which
blocked the aortic valve.” In 1806, Jean Nicolas Corvisart
coined the term “vegetations” and suggested—as they were
similar to the venereal “cauliflower”—that they may be
caused by syphilis (2). Corvisart’s pupil Theophile Lae¨nnec
devised the stethoscope in 1816. This enabled Corvisart to
document the various murmurs that occur in IE, yet the
cause and systemic complications of IE remained a mystery.
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In 1852 William Senhouse Kirkes described findings due
to breaking off of parts of the vegetations that subsequently
became lodged in blood vessels of various organs (3). It was
Rudolf Virchow who, in his Die Cellularpathologie, called
this phenomenon “embolism” after seeing that the “throm-
bi” lodged in blood vessels bore a strong resemblance under
the microscope to vegetations (4). Virchow also described
“small granules” within these vegetations. These “bacteria,
vibros, and micrococci,” he concluded in 1871, were “veg-
etal” and not “pathological” in IE (4). However, Emmanuel
Winge presented a case of endocarditis in 1869 and pro-
posed that these granules were “parasitic” organisms and
had entered through the skin before becoming involved in
the disease on the heart valves. This debate continued until
the arrival of ideas on infection by Louis Pasteur and Robert
Koch. It was Arnold Netter who in 1881 as a student
described the then novel practice of culturing blood from
patients with endocarditis and subsequently inoculating
animals with the growth of bacteria. His supervisor Joseph
Grancher in 1884 coined the term “infectious” endocarditis
in recognition of the fact that no single microbe was the sole
cause of endocarditis.
William Osler was the first to realize that IE occurred on
valves previously damaged by rheumatic fever or congenital
valve disease and proposed that platelets were deposited
from the bloodstream to cause vegetations (5). Osler then
devised the terms “acute” and “chronic” for the two clinical
extremes of IE. Osler’s ability of clinical synthesis meant
that his name was posthumously awarded to many aspects of
IE, such as Osler’s nodes. Emmanuel Libman went on to
further classify acute IE, which was fatal within days, and
“Osler’s subacute” IE, which lasted weeks to months. In
1911 in New York, Libman saw Gustav Mahler who had
been diagnosed with “mitral contraction” (6). Mahler had
developed a sore throat while in New York and shortly
afterwards began to have fevers. Streptococcus viridans grew
in his blood culture, and he died some three months later at
the age of 51, never finishing the Tenth Symphony. Thus,
IE remained a deadly ailment until the 1940s when the
development of penicillin made IE potentially curable.
Although the incidence of IE has remained stable at 1.7
to 6.2 cases per 100,000 person-years, the clinical profile has
continued to evolve (7). Thus, successive surveys of IE
drawing from the same population have continued to detect
changes in its clinical picture even over a period of 10 years
(8). In the developed world, the chronic form of IE
described by Osler has been superseded by a more rapidly
diagnosed and fulminant illness. Men still outnumber
women (1.7:1), but the median age has increased from 30 to
40 years in the pre-antibiotic era to 47 to 69 years recently
(7). Consequently, degenerative valve disease and prosthetic
valve IE have become more common rather than rheumatic
heart disease. Prosthetic valve IE now accounts for 16% to
31% in some surveys (8,9). Concurrently IE has become
more common in those with hemodialysis, diabetes melli-
tus, intravenous drug use, and nosocomial infections (7).
As the presence of vegetations is pathognomic of the IE,
it is not surprising that the sole means of visualizing them in
vivo has become integral to its diagnosis. The first report of
M-mode echocardiography to visualize bacterial vegetations
was made in 1973 by Dillon et al. (10). Since then,
technological advances, including the advent of transesoph-
ageal echocardiography, have significantly improved the
ability to detect vegetations, particularly on the prosthetic
valves, and to make an accurate diagnosis of abscess (11).
Cardiac and neurologic complications of IE, including
septic micro-embolization, have the largest effect on long-
term survival (7). Embolization occurs in approximately
11% to 25% of the patients with IE, and results in death in
24% to 50% of those who sustain an embolus (12,13).
Assuming the prevalence of IE to be 5/100,000 population
and the incidence of embolization conservatively to be 20%,
approximately 2,800 people experience embolic events re-
lated to IE every year in the U.S. (14). Highly mobile
vegetations 10 mm in size on transesophageal echocardi-
ography have been shown to have a higher incidence of
embolization (15–17). The type of organism involved may
influence the likelihood of embolization with Streptococcus
viridans (18) or Staphylococcus aureus (19) associated with a
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higher incidence of embolization. Other studies have found
that vegetations on either right-sided valves or the mitral
valves are more likely to embolize (16,17,19). When present
in patients with IE, anti-phospholipid antibodies and sol-
uble adhesion molecules are more likely to lead to emboli-
zation (20,21). Conversely, patients with no discernable
vegetations can still suffer from embolic events secondary to
the immunologic and hematologic changes in the blood
resulting from infection (22). Thus, the underlying patho-
genesis of embolization has a complex etiology.
As surgical techniques have improved, earlier interven-
tion has improved overall survival rates (23). The strongest
indications for surgery are congestive heart failure due to
damaged valves, uncontrolled infection including abscess
formation, and relapse after appropriate medical therapy (7).
As most embolization occurs before antibiotic treatment,
the role for surgery in preventing this complication is
undefined. As such, the mainstay of current treatment of IE
is an accurate antibiotic therapy, with possible surgical
intervention. The addition of antiplatelet agents or antico-
agulants to this regimen is aimed to potentially reduce the
risk of embolization further.
Initial formation of vegetation is thought to result from
adhesion of platelets to the collagen-rich subendothelial
stroma exposed by superficial damage to the valve surface
(24). Subsequent propagation of a vegetation relies on
continued fibrin deposition and platelet aggregation (25).
Thus, antiplatelet agents may reduce the risk of emboliza-
tion, especially as aspirin has been shown to protect other
vascular events. Indeed, in experimental models of IE,
aspirin reduced bacterial titers as well as vegetation size and
in some but not all studies reduced the risk of embolization
(26–28). Other antiplatelet agents such as sulphinpyrazone
(29), and ticlopidine with or without aspirin (28) showed
promising results in animal models. An early clinical study,
although only containing nine subjects, suggested a possible
protective role for aspirin in IE (30). Warfarin, on the other
hand, has not been shown in experimental studies to reduce
vegetation size (31,32). Several non-randomized studies
suggested that warfarin may in fact increase the rate of
cerebral hemorrhage especially in those with Staphylococcus
species IE (13,33,34).
With this as a backdrop, the study by Chan et al. (35)
reported in this issue of the Journal addresses the efficacy of
aspirin in reducing the rate of embolic events in a rigorous
fashion. A total of 115 patients with documented IE from
19 centers in Canada and the U.S. were double-blindly
assigned to receive aspirin or placebo. Patients were fol-
lowed for the primary outcome of clinical embolism, and
secondary outcome of computed tomography (CT) detected
subclinical stroke, death, and hemorrhage. After four weeks
of follow-up, the rate of clinical embolization was 28.3% in
the aspirin group compared with 20% in the placebo group
without a significant difference. Although not reaching
statistical significance, the rate of combined major and
minor hemorrhage tended to be higher in the aspirin group
(28.8%) compared with the placebo group (14.5%). At the
end of the study, 70% of the patients underwent head CT
demonstrating significant lesions in 39.5% of the patients on
aspirin compared with 29.3% in the placebo group. In 42%
of the patients undergoing transesophageal echocardiogra-
phy at the onset and end of the study, vegetation size
decreased to a similar extent between the two arms, and
there was no significant difference in the degree of valvular
regurgitation. This study thus demonstrates that despite
promising experimental data aspirin does not benefit pa-
tients with IE.
However, readers are cautioned that notwithstanding this
study, aspirin may still be beneficial for the subset of
patients with IE. There may be a differential benefit of
aspirin, depending on the site of vegetation, the size of the
vegetation, or the valve type. The type of offending organ-
ism may be an important factor, because much of the
preliminary experimental data originated from the use of
Staphylococcus species which may have different properties
compared with other pathogens (32). Unfortunately, the
number of patients with different types of infection in the
Chan et al. (35) series is too small for analysis. As the
authors correctly point out, another potential problem is the
dose of aspirin used. The dose may not have reflected that
used in the experimental studies, some of which used the
intravenous route. Also, the experimental studies used
aspirin at the outset of the infection, but the use of aspirin
in the clinical setting is understandably delayed until diag-
nosis, which in a large fraction of cases occurs weeks from
the symptom onset. Another limitation of the study is the
difficulty in using echocardiography to assess vegetation
size, which has a significant variability.
The neurologic consequences of embolization are devas-
tating. Therefore, the development of treatment strategies
to prevent this complication in IE should remain at the
forefront of future research. What is currently lacking is a
comprehensive approach to prevent embolism in patients
with IE that takes into account echocardiographic findings,
the site and the type of valve involved, the offending
organism, as well as the role of serum markers such as
anti-phospholipid antibody and adhesion molecules. The
risk of embolization may eventually be assessed from the
combination of factors and from the efficacy of therapeutic
modalities considered. Future studies as part of the Inter-
national Collaboration on Endocarditis may demonstrate a
role for aspirin in a specific subgroup with IE (14). Mean-
while, the study by Chan et al. (35) shows that blanket
therapy with aspirin is not warranted at this time. Our
knowledge of IE evolves with time, and it is with carefully
performed studies such as this that we will have information
to benefit our patients.
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